Tags

Type your tag names separated by a space and hit enter

Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens.
J Pept Sci. 2017 Apr; 23(4):329-333.JP

Abstract

Infection sustained by multidrug-resistant and extensively drug-resistant bacterial pathogens is often untreatable with the standard of care antibiotics, and the combination of anti-infective compounds often represents the only therapeutic strategy to face this major clinical treat. SET-M33 is a novel antimicrobial peptide (AMP) that has demonstrated in vitro and in vivo antimicrobial activity against Gram-negative bacteria and has shown interesting features in preclinical evaluations. Particularly, it showed efficacy against a number of multidrug-resistant and extensively drug-resistant clinical strains of Gram-negative pathogens, in in vitro and in vivo assessments. Here, we explored the potential synergistic activity of SET-M33 in combination with different standard of care antibiotics by the checkerboard method against a panel of six strains of Gram-negative pathogens including multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. SET-M33 showed synergistic activity with antibiotics of different families against these clinically relevant strains. A synergistic effect was observed for SET-M33 in combination with rifampin, meropenem, aztreonam, and tobramycin mostly on K. pneumoniae and A. baumannii strains, while the SET-M33 plus ciprofloxacin combination was additive with all tested strains. Synergy was not apparently linked to the bacterial species or phenotype but was rather strain-specific, highlighting the need for individual strain testing for synergistic antimicrobial combinations. These findings extend current knowledge on synergistic activity of AMPs in combination with conventional agents and support the potential role of SET-M33 as a novel therapeutic agent against antibiotic-resistant Gram-negative pathogens. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.

Authors+Show Affiliations

Department of Medical Biotechnologies, University of Siena, Siena, Italy. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.Department of Medical Biotechnologies, University of Siena, Siena, Italy.Department of Medical Biotechnologies, University of Siena, Siena, Italy.Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. Clinical Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy. Don Carlo Gnocchi Foundation, Florence, Italy.Department of Medical Biotechnologies, University of Siena, Siena, Italy.Department of Medical Biotechnologies, University of Siena, Siena, Italy.Department of Medical Biotechnologies, University of Siena, Siena, Italy. Setlance srl, Siena, Italy.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28176481

Citation

Pollini, Simona, et al. "Synergistic Activity Profile of an Antimicrobial Peptide Against Multidrug-resistant and Extensively Drug-resistant Strains of Gram-negative Bacterial Pathogens." Journal of Peptide Science : an Official Publication of the European Peptide Society, vol. 23, no. 4, 2017, pp. 329-333.
Pollini S, Brunetti J, Sennati S, et al. Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. J Pept Sci. 2017;23(4):329-333.
Pollini, S., Brunetti, J., Sennati, S., Rossolini, G. M., Bracci, L., Pini, A., & Falciani, C. (2017). Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. Journal of Peptide Science : an Official Publication of the European Peptide Society, 23(4), 329-333. https://doi.org/10.1002/psc.2978
Pollini S, et al. Synergistic Activity Profile of an Antimicrobial Peptide Against Multidrug-resistant and Extensively Drug-resistant Strains of Gram-negative Bacterial Pathogens. J Pept Sci. 2017;23(4):329-333. PubMed PMID: 28176481.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Synergistic activity profile of an antimicrobial peptide against multidrug-resistant and extensively drug-resistant strains of Gram-negative bacterial pathogens. AU - Pollini,Simona, AU - Brunetti,Jlenia, AU - Sennati,Samanta, AU - Rossolini,Gian Maria, AU - Bracci,Luisa, AU - Pini,Alessandro, AU - Falciani,Chiara, Y1 - 2017/02/08/ PY - 2016/12/02/received PY - 2017/01/13/revised PY - 2017/01/16/accepted PY - 2017/2/9/pubmed PY - 2017/5/10/medline PY - 2017/2/9/entrez KW - antimicrobial KW - antimicrobial synergy KW - bacteria resistances KW - branched KW - peptide SP - 329 EP - 333 JF - Journal of peptide science : an official publication of the European Peptide Society JO - J. Pept. Sci. VL - 23 IS - 4 N2 - Infection sustained by multidrug-resistant and extensively drug-resistant bacterial pathogens is often untreatable with the standard of care antibiotics, and the combination of anti-infective compounds often represents the only therapeutic strategy to face this major clinical treat. SET-M33 is a novel antimicrobial peptide (AMP) that has demonstrated in vitro and in vivo antimicrobial activity against Gram-negative bacteria and has shown interesting features in preclinical evaluations. Particularly, it showed efficacy against a number of multidrug-resistant and extensively drug-resistant clinical strains of Gram-negative pathogens, in in vitro and in vivo assessments. Here, we explored the potential synergistic activity of SET-M33 in combination with different standard of care antibiotics by the checkerboard method against a panel of six strains of Gram-negative pathogens including multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii. SET-M33 showed synergistic activity with antibiotics of different families against these clinically relevant strains. A synergistic effect was observed for SET-M33 in combination with rifampin, meropenem, aztreonam, and tobramycin mostly on K. pneumoniae and A. baumannii strains, while the SET-M33 plus ciprofloxacin combination was additive with all tested strains. Synergy was not apparently linked to the bacterial species or phenotype but was rather strain-specific, highlighting the need for individual strain testing for synergistic antimicrobial combinations. These findings extend current knowledge on synergistic activity of AMPs in combination with conventional agents and support the potential role of SET-M33 as a novel therapeutic agent against antibiotic-resistant Gram-negative pathogens. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd. SN - 1099-1387 UR - https://www.unboundmedicine.com/medline/citation/28176481/Synergistic_activity_profile_of_an_antimicrobial_peptide_against_multidrug_resistant_and_extensively_drug_resistant_strains_of_Gram_negative_bacterial_pathogens_ L2 - https://medlineplus.gov/antibiotics.html DB - PRIME DP - Unbound Medicine ER -